Targeting HER2-positive Metastatic Breast Cancer
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients with advanced or metastatic breast cancer
Progress Against Cancer
The FDA has expanded the use of the molecularly targeted therapeutic neratinib to include the treatment of certain patients with advanced or metastatic breast cancer
The FDA has approved a molecularly targeted therapy for epithelioid sarcoma, the first treatment approved for this rare form of soft tissue sarcoma.
The FDA has approved a molecularly targeted treatment for certain patients with gastrointestinal stromal tumors.
The FDA approved the use of the targeted therapeutic olaparib to treat certain pancreatic cancer patients whose disease has metastasized.
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted therapies.
The FDA approved a molecularly targeted therapeutic for patients with advanced or metastatic urothelial cancer.
The FDA approved a molecularly targeted therapy to treat patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the...
The FDA approved the immune checkpoint inhibitor pembrolizumab in combination with the molecularly targeted therapeutic lenvatinib for women with advanced endometrial cancer.
The FDA has approved a molecularly targeted therapeutic for treating certain adults with a rare blood cancer called myelofibrosis.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More